Summary:
A phase III, multicenter, international, randomized, parallel group, double blind cardiovascular safety study of BI 100773 (10mg and 25mg administered orally once daily) compared to usual care in Type 2 diabetes patients with increased cardiovascular risk.
Qualified Participants Must:
• Be at least 18 years of age
•
Be diagnosed with Type 2 diabetes
•
Be able to provide medical records
Qualified Participants May Receive:
Study medication, study-related medical care, and may receive compensation.